CrystalGenomics, Inc. (083790.KQ)
KRW 2545.0
(0.99%)
KRW 2545.0
(0.99%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 8.99 Billion USD | -77.65% |
| 2022 | 40.23 Billion USD | -8.07% |
| 2021 | 43.76 Billion USD | 198.04% |
| 2020 | 14.68 Billion USD | 184.95% |
| 2019 | 5.15 Billion USD | 2465.99% |
| 2018 | -217.82 Million USD | 25.73% |
| 2017 | -293.27 Million USD | -54.57% |
| 2016 | -189.73 Million USD | -8.23% |
| 2015 | -175.3 Million USD | -40.83% |
| 2014 | -124.48 Million USD | 12.45% |
| 2013 | -142.19 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 8.66 Billion KRW | -3.62% |
| 2024 Q2 | 6.64 Billion KRW | -82.05% |
| 2023 FY | 8.99 Billion USD | -77.65% |
| 2023 Q1 | 51.77 Billion USD | 28.69% |
| 2023 Q3 | 25.4 Billion USD | 63.08% |
| 2023 Q2 | 15.57 Billion KRW | -69.92% |
| 2023 Q4 | 8.99 Billion USD | -64.6% |
| 2022 FY | 40.23 Billion USD | -8.07% |
| 2022 Q3 | 8.91 Billion USD | 0.0% |
| 2022 Q1 | 8.45 Billion USD | 3630.96% |
| 2022 Q4 | 40.23 Billion USD | 351.41% |
| 2021 Q4 | -239.42 Million USD | 79.56% |
| 2021 FY | 43.76 Billion USD | 198.04% |
| 2021 Q1 | -975.64 Million USD | 41.37% |
| 2021 Q3 | -1.17 Billion USD | 0.0% |
| 2020 Q1 | -509.11 Million USD | -222.05% |
| 2020 Q4 | -1.66 Billion USD | 4.96% |
| 2020 FY | 14.68 Billion USD | 184.95% |
| 2020 Q3 | -1.75 Billion USD | 0.0% |
| 2019 FY | 5.15 Billion USD | 2465.99% |
| 2019 Q4 | -158.08 Million USD | 10.33% |
| 2019 Q1 | -174.05 Million USD | 11.04% |
| 2019 Q3 | -176.3 Million USD | 0.0% |
| 2018 Q1 | -218.38 Million USD | 24.31% |
| 2018 FY | -217.82 Million USD | 25.73% |
| 2018 Q4 | -195.66 Million USD | 10.17% |
| 2018 Q3 | -217.82 Million USD | 0.0% |
| 2017 Q1 | -227.14 Million USD | -7.83% |
| 2017 Q4 | -288.52 Million USD | 1.62% |
| 2017 Q3 | -293.27 Million USD | 0.0% |
| 2017 FY | -293.27 Million USD | -54.57% |
| 2016 Q1 | -213.38 Million USD | -2.61% |
| 2016 Q3 | -189.73 Million USD | 0.0% |
| 2016 Q4 | -210.64 Million USD | -11.02% |
| 2016 FY | -189.73 Million USD | -8.23% |
| 2015 Q1 | -153.28 Million USD | -30.8% |
| 2015 FY | -175.3 Million USD | -40.83% |
| 2015 Q4 | -207.95 Million USD | -18.62% |
| 2015 Q3 | -175.3 Million USD | 0.0% |
| 2014 Q1 | -145.34 Million USD | -15.49% |
| 2014 FY | -124.48 Million USD | 12.45% |
| 2014 Q4 | -117.19 Million USD | 5.86% |
| 2014 Q3 | -124.48 Million USD | 0.0% |
| 2013 Q4 | -125.85 Million USD | 11.49% |
| 2013 Q3 | -142.19 Million USD | 0.0% |
| 2013 FY | -142.19 Million USD | 0.0% |
| 2013 Q1 | -133.68 Million USD | -15.7% |
| 2012 Q4 | -115.54 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| HLB Co., Ltd. | -46.18 Billion KRW | 119.47% |
| iNtRON Biotechnology, Inc. | -40.58 Billion KRW | 122.156% |
| BINEX Co., Ltd. | 45.34 Billion KRW | 80.171% |
| Bioneer Corporation | -3.9 Billion KRW | 330.102% |
| Anterogen.Co.,Ltd. | 8.35 Billion KRW | -7.664% |
| MEDIPOST Co., Ltd. | 14.81 Billion KRW | 39.303% |
| Helixmith Co., Ltd | -24.42 Billion KRW | 136.813% |
| Chabiotech Co.,Ltd. | 388.94 Billion KRW | 97.688% |
| Medy-Tox Inc. | 49.58 Billion KRW | 81.865% |
| Peptron, Inc. | 4.86 Billion KRW | -84.691% |
| Amicogen, Inc. | 125.26 Billion KRW | 92.822% |
| Genexine, Inc. | 61.39 Billion KRW | 85.354% |
| HLB Therapeutics Co.,Ltd. | -13.68 Billion KRW | 165.698% |
| LegoChem Biosciences, Inc. | -56.05 Billion KRW | 116.042% |
| ALTEOGEN Inc. | 53.56 Billion KRW | 83.215% |
| PharmaResearch Co., Ltd. | -32.93 Billion KRW | 127.299% |
| SillaJen, Inc. | -13.89 Billion KRW | 164.729% |
| JETEMA, Co., Ltd. | 84.27 Billion KRW | 89.331% |
| OliX Pharmaceuticals,Inc | 27.37 Billion KRW | 67.153% |
| Genomictree Inc. | -43.43 Billion KRW | 120.702% |
| MedPacto, Inc. | -64 Billion KRW | 114.05% |
| D&D Pharmatech | -7.5 Billion KRW | 219.767% |
| EASY BIO,Inc. | 53.21 Billion KRW | 83.101% |
| GI Innovation, Inc. | -4.82 Billion KRW | 286.457% |